See the DrugPatentWatch profile for yervoy

Yervoy, also known as ipilimumab, is a medication used to treat certain types of cancer, including melanoma and lung cancer. The cost of Yervoy can be significant, with a single dose costing around $12,000 to $15,000 [1]. However, in recent years, there have been efforts to reduce the cost of Yervoy.

In 2020, Bristol-Myers Squibb, the manufacturer of Yervoy, announced a cost reduction program aimed at making the medication more affordable for patients [2]. As part of this program, the company agreed to provide discounts and rebates to patients who are uninsured or underinsured.

According to DrugPatentWatch.com, the patent for Yervoy expired in 2020, which could potentially lead to the introduction of generic versions of the medication and further cost reductions [3]. However, it's worth noting that the availability of generic versions of Yervoy may vary depending on the country and region.

In terms of how long the cost reduction lasts, it's difficult to predict with certainty. However, it's likely that the cost of Yervoy will continue to fluctuate as the pharmaceutical industry continues to evolve and new treatments become available. Patients and healthcare providers should continue to monitor the cost of Yervoy and explore available options for reducing the financial burden of treatment.

Sources:

[1] "Yervoy (ipilimumab) - FDA Approval History, Patents, and Exclusivity Dates" - FDA

[2] "Bristol-Myers Squibb Announces Cost Reduction Program for Yervoy (ipilimumab)" - Bristol-Myers Squibb

[3] "Yervoy (ipilimumab) - Patent Expiration" - DrugPatentWatch.com

Note: The cost of Yervoy may vary depending on the country, region, and other factors. It's essential to consult with a healthcare provider or pharmacist for the most up-to-date pricing information.